KR101462065B1 - Oral pharmaceutical composition for sustained release containing guanfacine - Google Patents
Oral pharmaceutical composition for sustained release containing guanfacine Download PDFInfo
- Publication number
- KR101462065B1 KR101462065B1 KR1020120146171A KR20120146171A KR101462065B1 KR 101462065 B1 KR101462065 B1 KR 101462065B1 KR 1020120146171 A KR1020120146171 A KR 1020120146171A KR 20120146171 A KR20120146171 A KR 20120146171A KR 101462065 B1 KR101462065 B1 KR 101462065B1
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- release
- sustained
- lactose
- diluent
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
Abstract
본 발명은 구안파신 2 중량%에 희석제로서 유당 55∼65 중량%와 중성 수팽윤성 방출 제어용 고분자로서 하이드록시프로필메틸셀룰로스 13∼17 중량%, 음이온성 수팽윤성 방출 제어용 고분자로서 폴리아크릴산나트륨 13∼17 중량%, 붕해제로서 크로스카멜로스나트륨 3∼5 중량%, 결합제로서 폴리비닐피롤리돈 2∼4 중량% 및 윤활제로서 스테아르산마그네슘 0.8∼1.2 중량%를 혼합시켜 과립화시킨 후 타정시켜 제조된 구안파신 서방성 정제 조성물에 관한 것이다.The present invention relates to a composition comprising 2 to 20% by weight of guanaxanthin, 55 to 65% by weight of lactose as a diluent, 13 to 17% by weight of hydroxypropylmethyl cellulose as a neutral water swellable release controlling polymer, and sodium polyacrylate 13 to 17 as an anionic water- , 3 to 5% by weight of croscarmellose sodium as a disintegrant, 2 to 4% by weight of polyvinylpyrrolidone as a binder, and 0.8 to 1.2% by weight of magnesium stearate as a lubricant, ≪ / RTI > sustained release tablet compositions.
Description
본 발명은 구안파신(guanfacine)을 활성 성분으로 함유하는 경구용 서방성 약제학적 조성물에 관한 것이다. 더욱 상세하게는 주의력 결핍 과잉행동장애(ADHD)의 치료에 사용되는 구안파신의 경구용 서방성 정제의 약제학적 조성물에 관한 것이다.
The present invention relates to an oral sustained release pharmaceutical composition containing guanfacine as an active ingredient. And more particularly to pharmaceutical compositions of oral sustained release tablets of guanaxan used in the treatment of attention deficit hyperactivity disorder (ADHD).
N-(디아미노메틸리덴)-2-(2,6-디클로로페닐)아세트아미드의 화학명을 지닌 하기 식 Ⅰ로 나타나는 구안파신 또는 그의 염산염은 선택적 알파2 A-아드레날린 수용체 효용제로 알려져 있으며 수축기 및 이완기 혈압을 감소시키는 항 고혈압제로 사용되어 왔다. 그러나 최근 항 고혈압제로서의 의약용도 이외에 주의력 결핍 과잉행동장애(ADHD)의 치료제로서 FDA로부터 승인 받고 임상에 적용되고 있다.
Guanaxanine or its hydrochloride, represented by the formula I, having the chemical name of N - (diaminomethylidene) -2- (2,6-dichlorophenyl) acetamide, is known as a selective alpha 2 A -adrenoceptor receptor antagonist and has a systolic and diastolic Has been used as an antihypertensive agent for reducing blood pressure. However, recently, it has been approved by the FDA as a therapeutic agent for attention deficit hyperactivity disorder (ADHD) in addition to its use as an antihypertensive agent and has been applied to clinical practice.
주의력 결핍/과잉행동 장애(ADHD)는 아동기에 많이 나타나는 장애로 지속적으로 주의력이 부족하여 산만하고 과다활동 충동성을 보이는 상태를 말한다. 이러한 증상들을 치료하지 않고 방치할 경우 아동기 내내 여러 방면에서 어려움이 지속되고 일부의 경우 청소년기와 성인기가 되어서도 증상이 남게 된다.
Attention deficit / hyperactivity disorder (ADHD) is a condition characterized by many disturbances in childhood characterized by distracted and hyperactivity impulsivity due to lack of continuous attention. When these symptoms are left untreated, difficulties persist in various ways throughout childhood, and in some cases symptoms persist even in adolescence and adulthood.
그러나 이 질환의 정확한 원인은 현재까지 알려진 바가 없으나 뇌영상 촬영에서 정상인에 비해 활동과 주의집중을 조절하는 부위의 뇌 활성이 떨어지는 소견이 관찰되며 이 부위의 구조적 차이도 발견되고 있다.
However, the exact cause of this disease is not known until now, but the brain activity of the area that controls activity and attention is lower than that of the normal person.
ADHD에는 약물치료가 효과적이다. 약물 치료를 통해 80% 정도가 분명한 호전을 보이는데 집중력 기억력 학습능력이 전반적으로 좋아진다. 이러한 ADHD의 효과적 약물로서 최근 구안파신이 각광받고 있다.
Medication is effective for ADHD. Drug therapy has shown a clear improvement in 80% of patients. Recently, as an effective drug for ADHD, it has become popular.
구안파신은 물에 대한 용해성이 높고 생체 이용률 역시 우수한 약물로 알려져 있고 신장을 통해 쉽게 배출된다. 그러나 구안파신은 응집성 및 결정구조와 관련된 인자 때문에 그 제제화가 통상적인 정제 또는 캡슐제와 같은 경구용 제제로 제형화시킬 때에는 적정한 입도를 지닌 구안파신 미세 분말을 균질하게 분산시켜 부형제와 적절한 조건하에서 경구용 제제로 제형화시켜야 하는 어려움이 있었던 것이다.
Guanaxin is known as a drug that has high solubility in water and good bioavailability, and is easily released through the kidneys. However, due to factors related to cohesiveness and crystal structure, guanaxan is dispersed homogeneously in the form of an oral preparation such as tablets or capsules, which has a proper particle size, There was a difficulty in formulation into a drug formulation.
한편으로는 구안파신은 소아 또는 청소년에게 경구 투여하는 약물이므로 용법 용량을 개선시켜 1일 1회 투여 용량으로의 경구 투여 제형이 요구되며 따라서 인체 내에서 지속적 방출 특성을 지닌 서방성 정제 형태의 경구 투여 형태의 개발이 요구되어왔던 것이다.
On the other hand, since Guanaxin is a drug to be administered orally to children or adolescents, it is necessary to improve oral administration dosage by once-a-day dose, and thus oral administration in the form of sustained-release tablets The development of the form has been demanded.
따라서 본 발명자들은 구안파신의 적절한 입도를 조절하여 균질하게 분산시킨 후 적절한 부형제로 과립화시킨 정제형 경구 투여 제형을 개발하던 중, 구안파신에 희석제로 유당, 중성 수팽윤성 방출 제어용 고분자로서 하이드록시프로필메틸셀룰로스(HPMC), 음이온성 수팽윤성 방출 제어용 고분자로서 폴리아크릴산나트륨, 붕해제로 크로스카멜로스나트륨, 결합제로 폴리비닐피롤리돈, 윤활제로 스테아르산마그네슘을 사용할 때 최적의 지속적 방출 특성을 지닌 구안파신 서방성 정제를 제조할 수 있음을 발명함으로써 본 발명을 완성하게 된 것이다
Accordingly, the inventors of the present invention have developed a tablet-type oral dosage form in which an appropriate particle size of guanaxanthin was controlled and dispersed homogeneously and granulated with an appropriate excipient, and then, as a diluent for diluent, a lactose for hydroxyapatite, Methylcellulose (HPMC), sodium polyacrylate as an anionic water-swellable release-controlling polymer, croscarmellose sodium as a disintegrant, polyvinylpyrrolidone as a binder, magnesium stearate as a lubricant, The inventors of the present invention have completed the present invention by inventing that the sustained-
따라서 본 발명이 해결하고자 하는 과제는 구안파신의 적절한 입도를 조절하여 균질하게 분산시킨 후 적절한 부형제로 과립화시킨 정제형 경구 투여 제형을 개발코자 한 것이다. 구안파신에 희석제로 유당, 중성 수팽윤성 방출 제어용 고분자로서 하이드록시프로필메틸셀룰로스(HPMC), 음이온성 수팽윤성 방출 제어용 고분자로서 폴리아크릴산나트륨, 붕해제로 크로스카멜로스나트륨, 결합제로 폴리비닐피롤리돈, 윤활제로 스테아르산마그네슘을 사용함으로써 최적의 지속적 방출 특성을 지닌 구안파신 서방성 정제를 개발코자 한 것이다.
Accordingly, a problem to be solved by the present invention is to develop a tablet-type oral dosage form in which an appropriate particle size of guanaxanthin is controlled to be homogeneously dispersed and granulated with an appropriate excipient. (HPMC) as a polymer for swelling control of neutral water, sodium polyacrylate as an anionic water-swellable release-controlling polymer, croscarmellose sodium as a disintegrating agent, polyvinylpyrrolidone , And magnesium stearate as a lubricant to develop a sustained-release sustained-release tablets.
본 발명의 목적은 구안파신 2 중량%에 희석제로서 유당 55∼65 중량%와 중성 수팽윤성 방출 제어용 고분자로서 하이드록시프로필메틸셀룰로스 13∼17 중량%, 음이온성 수팽윤성 방출 제어용 고분자로서 폴리아크릴산나트륨 13∼17 중량%, 붕해제로서 크로스카멜로스나트륨 3∼5 중량%, 결합제로서 폴리비닐피롤리돈 2∼4 중량% 및 윤활제로서 스테아르산마그네슘 0.8∼1.2 중량%를 혼합시켜 과립화시킨 후 타정시켜 제조된 구안파신 서방성 정제 조성물을 제공하는 것이다.
The object of the present invention is to provide a liquid composition for oral administration which comprises 55 to 65% by weight of lactose as a diluent, 13 to 17% by weight of hydroxypropylmethyl cellulose as a neutral water-swellable release-controlling polymer, 2 to 13% by weight of sodium polyacrylate To 17% by weight of a disintegrant, 3 to 5% by weight of croscarmellose sodium as a disintegrant, 2 to 4% by weight of polyvinylpyrrolidone as a binder and 0.8 to 1.2% by weight of magnesium stearate as a lubricant, And to provide a sustained release sustained-release tablet composition of guanaxan.
이때 유효 활성성분인 구안파신의 함량은 0.5∼4mg 임을 특징으로 한다.
In this case, the content of guanofasin, which is an active active ingredient, is 0.5 to 4 mg.
본 발명의 또다른 목적은 ⅰ) 구안파신 2 중량%에 희석제로서 유당 55∼65 중량%와 중성 수팽윤성 방출 제어용 고분자로서 하이드록시프로필메틸셀룰로스 13∼17 중량%, 음이온성 수팽윤성 방출 제어용 고분자로서 폴리아크릴산나트륨 13∼17 중량%, 붕해제로서 크로스카멜로스나트륨 3∼5 중량%, 결합제로서 폴리비닐피롤리돈 2∼4 중량% 및 윤활제로서 스테아르산마그네슘 0.8∼1.2 중량%를 혼합시켜 혼합물의 입도를 500㎛ 이하로 세분말화시킨 후 과립화시키는 단계; 및 ⅱ) 건조된 과립화 혼합물을 정제로 압착 타정시키는 단계;로 이루어진 구안파신 서방성 정제 조성물의 제조 방법을 제공하는 것이다.
It is still another object of the present invention to provide a method for controlling an ionic swellable emulsion, comprising the steps of (i) adding 55 to 65% by weight of lactose as a diluent to 13% by weight of hydroxypropyl methylcellulose as a neutral water swelling control polymer, 13 to 17% by weight of sodium polyacrylate, 3 to 5% by weight of croscarmellose sodium as a disintegrant, 2 to 4% by weight of polyvinylpyrrolidone as a binder and 0.8 to 1.2% by weight of magnesium stearate as a lubricant, Granulating the mixture into fine particles having a particle size of not more than 500 탆; And ii) compressing and pressing the dried granulated mixture with a tablet, thereby providing a sustained-release sustained-release tablet composition.
본 발명의 또다른 목적은 상기 구안파신 서방성 정제 조성물을 주의력 결핍 과잉행동장애(ADHD) 치료제로서 사용하는 방법을 제공하는 것이다.
It is another object of the present invention to provide a method for using the sustained-release sustained-release tablet composition as an agent for treating attention deficit hyperactivity disorder (ADHD).
본 발명의 효과는 구안파신의 적절한 입도를 조절하여 균질하게 분산시킨 후 적절한 부형제로 과립화시킨 정제형 경구 투여 제형을 제공하는 것이다. 구안파신에 희석제로 유당, 중성 수팽윤성 방출 제어용 고분자로서 하이드록시프로필메틸셀룰로스(HPMC), 음이온성 수팽윤성 방출 제어용 고분자로서 폴리아크릴산나트륨, 붕해제로 크로스카멜로스나트륨, 결합제로 폴리비닐피롤리돈, 윤활제로 스테아르산마그네슘을 사용함으로써 최적의 지속적 방출 특성을 지닌 구안파신 서방성 정제를 제공하는 것이다.
The effect of the present invention is to provide a tablet-type oral dosage form in which the appropriate particle size of guanaxanthin is controlled to be homogeneously dispersed and then granulated with a suitable excipient. (HPMC) as a polymer for swelling control of neutral water, sodium polyacrylate as an anionic water-swellable release-controlling polymer, croscarmellose sodium as a disintegrating agent, polyvinylpyrrolidone , And magnesium stearate as a lubricant, thereby providing a sustained-release sustained-release tablets.
도 1은 제조실시예 1, 제조비교예 1, 3, 4, 5에서 제조된 정제의 시간 변화에 따른 용출율을 나타내는 그래프이다.FIG. 1 is a graph showing dissolution rates of tablets prepared in Production Example 1, Comparative Production Examples 1, 3, 4 and 5 with time. FIG.
본 발명은 구안파신 2 중량%에 희석제로서 유당 55∼65 중량%와 중성 수팽윤성 방출 제어용 고분자로서 하이드록시프로필메틸셀룰로스 13∼17 중량%, 음이온성 수팽윤성 방출 제어용 고분자로서 폴리아크릴산나트륨 13∼17 중량%, 붕해제로서 크로스카멜로스나트륨 3∼5 중량%, 결합제로서 폴리비닐피롤리돈 2∼4 중량% 및 윤활제로서 스테아르산마그네슘 0.8∼1.2 중량%를 혼합시켜 과립화시킨 후 타정시켜 제조된 구안파신 서방성 정제 조성물에 관한 것이다.
The present invention relates to a composition comprising 2 to 20% by weight of guanaxanthin, 55 to 65% by weight of lactose as a diluent, 13 to 17% by weight of hydroxypropylmethyl cellulose as a neutral water swellable release controlling polymer, and sodium polyacrylate 13 to 17 as an anionic water- , 3 to 5% by weight of croscarmellose sodium as a disintegrant, 2 to 4% by weight of polyvinylpyrrolidone as a binder, and 0.8 to 1.2% by weight of magnesium stearate as a lubricant, ≪ / RTI > sustained release tablet compositions.
상기 구안파신 서방성 정제 조성물에 사용되는 희석제로서는 유당 44∼50 중량%를 사용하였다. 이러한 희석제는 담체 물질로서 함유되는 것이다. 상기한 희석제를 사용할 때 구안파신의 방출 속도, 안정성, 유동성 및 건조 특성이 최대로 유지된다.
As the diluent used in the sustained-release sustained-release tablet composition, 44 to 50% by weight of lactose was used. Such a diluent is contained as a carrier material. When the above-mentioned diluent is used, the release rate, stability, flowability and drying property of the goofy gum are maximized.
희석제로 사용되는 유당의 경우 락토오즈, 무수락토오즈, 락토오즈 1 수화물, 분무 건조된 락토오즈 등을 사용할 수 있다.
In the case of lactose used as a diluent, lactose, anhydrous lactose, lactose monohydrate, spray-dried lactose, and the like can be used.
또한 방출 제어용 고분자로서 중성 수팽윤성 방출 제어용 고분자 하이드록시프로필메틸셀룰로스 13∼17 중량%와 음이온성 수팽윤성 방출 제어용 고분자 폴리아크릴산나트륨 13∼17 중량%를 사용한다. 이는 상기 2종의 방출 제어용 고분자를 매트릭스 형태로 혼합시켜 구안파신의 방출을 제어하여 서방성 정제로 제조하기 위한 것이다.
13 to 17% by weight of a hydroxy-propylmethyl cellulose for neutral water-swellable release control and 13 to 17% by weight of a polymeric sodium polyacrylate for anionic water-swellable release control are used as a release-controlling polymer. This is for preparing a sustained-release tablet by mixing the two types of release-controlling polymers in a matrix form to control the release of the goethakusin.
일반적으로 중성 수팽윤성 중합체는 알킬셀룰로오스 하이드록시알킬셀룰로오스 카르복시알킬셀룰로오스 에스테르 기타 천연 반합성 또는 합성 디사카라이드 올리고사카라이드 및 폴리사카라이드 등을 사용할 수 있으나 본 발명에서는 하이드록시프로필메틸셀룰로오스(HPMC)를 사용한다. 이때 사용되는 HPMC의 경우 바람직한 점도는 60,000 cps 내지 120,000 cps 정도이고 점도가 120,000 cps를 초과하면 약물과의 균일한 혼합이 어려워진다.
Generally, the neutral water-swellable polymer may be an alkylcellulose hydroxyalkylcellulose carboxyalkylcellulose ester, other natural semisynthetic or synthetic disaccharide oligosaccharides, polysaccharides, etc. In the present invention, hydroxypropyl methylcellulose (HPMC) is used do. In the case of HPMC used herein, the preferred viscosity is about 60,000 cps to 120,000 cps, and when the viscosity exceeds 120,000 cps, uniform mixing with the drug becomes difficult.
또한 음이온성 수팽윤성 중합체는 아크릴산중합체 메타크릴산공중합체 알긴산염 키틴유도체 등을 사용할 수 있으나 본 발명에서는 아크릴산중합체 중 폴리아크릴산나트륨을 사용한다.
The anionic water-swellable polymer may be an acrylic acid polymer, a methacrylic acid copolymer, an alginate chitin derivative or the like. In the present invention, sodium polyacrylate is used in the acrylic acid polymer.
한편 구안파신 서방성 정제 조성물에 사용되는 붕해제로서는 크로스카멜로스나트륨 3∼5 중량%를 사용하고 크로스카멜로스나트륨은 우수한 과립 내 붕해 능력을 부여한다.
On the other hand, as the disintegrant used in the sustained-release sustained-release tablet composition, 3 to 5% by weight of croscarmellose sodium is used, and croscarmellose sodium gives excellent granule disintegration ability.
또한 구안파신 서방성 정제 조성물에 사용되는 결합제로서 폴리비닐피롤리돈 2∼4 중량%를 사용하고 이러한 결합제는 정제화되는 분말에 충분한 응집성을 부여함으로써 윤활, 압축 및 포장과 같은 각종 정제 제형화 조작을 용이하게 한다. 또한 폴리비닐피롤리돈은 과립화 분말 혼합물에 응집성을 제공하여 과립을 형성하는데 필요한 결합을 촉진시킨다. 폴리비닐피롤리돈을 함유하여 과립화시켜 제조된 본 발명의 서방성 정제 조성물은 상대적으로 우수한 생체 이용률을 나타내는 것이다.
In addition, 2 to 4% by weight of polyvinylpyrrolidone is used as the binder used in the Guanfassin sustained release tablet compositions, and this binder imparts sufficient cohesion to the powder to be tableted, thereby providing various tablet formulation operations such as lubrication, compression and packaging . The polyvinylpyrrolidone also provides cohesiveness to the granulated powder mixture to facilitate the binding necessary to form the granules. The sustained release tablet composition of the present invention prepared by granulating with polyvinylpyrrolidone exhibits relatively good bioavailability.
또한 구안파신 서방성 정제 조성물에 사용되는 윤활제로서 스테아르산마그네슘 0.8∼1.2 중량%를 사용한다. 스테아르산마그네슘은 정제 제형의 압축시 타정 압축 장치와 과립 혼합물간의 마찰력을 감소시켜 바람직한 형상으로 정제 제형을 제조할 수 있게 한다.
Also, 0.8 to 1.2% by weight of magnesium stearate is used as a lubricant for use in the sustained-release sustained-release tablet composition. Magnesium stearate reduces frictional forces between the tablet compression device and the granulation mixture during compression of the tablet formulation, thereby making it possible to produce the tablet formulation in the desired shape.
본 발명의 서방성 정제 조성물 내의 유효 활성성분인 구안파신의 함량은 0.5∼4mg 임을 특징으로 한다. 이는 통상 ADHD 치료시 1일 투여 함량이 4mg 이하임을 감안한 것으로 본 발명의 서방성 정제 조성물은 바람직하게는 1일 1회 투여하나 필요시 1일 2회 투여가 가능한 것이다.
The content of guanaxin as an active ingredient in the sustained-release tablet composition of the present invention is characterized by 0.5 to 4 mg. This is generally considered to be a dose of 4 mg or less per day when treating ADHD. The sustained release tablet composition of the present invention is preferably administered once a day, but can be administered twice a day if necessary.
한편 본 발명의 정제 제형의 제조 방법을 살펴보면 다음과 같다.
The preparation method of the tablet formulation of the present invention is as follows.
첫 번째 단계는 구안파신 30 중량%에 희석제로서 유당 44∼50 중량%, 중성 수팽윤성 방출 제어용 고분자로서 하이드록시프로필메틸셀룰로스 13∼17 중량%, 음이온성 수팽윤성 방출 제어용 고분자로서 폴리아크릴산나트륨 13∼17 중량%, 붕해제로서 크로스카멜로스나트륨 3∼5 중량%, 결합제로서 폴리비닐피롤리돈 2∼4 중량% 및 윤활제로서 스테아르산마그네슘 0.8∼1.2 중량%를 혼합시켜 혼합물의 입도를 500㎛ 이하로 조절시킨 후 과립화시키는 단계이다.
The first step is to add 30 to 50% by weight of guanosine hydrochloride as a diluent, 44 to 50% by weight of lactose as a diluent, 13 to 17% by weight of hydroxypropyl methylcellulose as a neutral water swellable release controlling polymer, and 13 to 20% by weight of sodium polyacrylate as an anionic water- 3 to 5% by weight of croscarmellose sodium as a disintegrant, 2 to 4% by weight of polyvinylpyrrolidone as a binder and 0.8 to 1.2% by weight of magnesium stearate as a lubricant are mixed so that the particle size of the mixture is not more than 500 탆 And then granulating it.
또한 두 번째 단계는 건조된 과립화 혼합물을 정제로 압착 타정시키는 단계이다. 이때 건조는 예를 들면 오븐 또는 유동층 건조기에서 건조됨으로써 건조 과립이 형성된다. 건조된 과립을 압착시켜 정제로 타정시키며 적당한 형태의 압착 장치 또는 타정 장치를 사용하여 정제로 압착 타정시키는 것이다.
The second step is to compress and dry the dried granulation mixture with a tablet. Drying is carried out, for example, in an oven or fluid bed dryer to form dried granules. The dried granules are squeezed and compressed into tablets, and the tablets are squeezed and compressed using a suitable type of squeezing device or tableting device.
이하 본 발명을 실시예 및 비교예를 통해 더욱 상세히 설명한다.
Hereinafter, the present invention will be described in more detail with reference to examples and comparative examples.
(제조실시예 1) 본 발명의 서방성 정제 조성물의 제조
(Production Example 1) Preparation of sustained release tablet composition of the present invention
구안파신 2 중량%에 희석제로서 유당 60 중량%, 중성 수팽윤성 방출 제어용 고분자로서 하이드록시프로필메틸셀룰로스 15 중량%, 음이온성 수팽윤성 방출 제어용 고분자로서 폴리아크릴산나트륨 15 중량%, 붕해제로서 크로스카멜로스나트륨 4 중량%, 결합제로서 폴리비닐피롤리돈 3 중량% 및 윤활제로서 스테아르산마그네슘 1.0 중량%를 혼합시켜 과립화시킨 후 타정시켜 제조된 구안파신 서방성 정제 조성물을 제조한다.
A mixture of 2% by weight of guanaxanthin, 60% by weight of lactose as a diluent, 15% by weight of hydroxypropyl methylcellulose as a polymer for neutral water-swellable release control, 15% by weight of sodium polyacrylate as an anionic water swellable release- 4% by weight of sodium, 3% by weight of polyvinylpyrrolidone as a binder, and 1.0% by weight of magnesium stearate as a lubricant were granulated and tableted to prepare a sustained release tablet composition of guanaxan.
(제조실시예 2) 본 발명의 서방성 정제 조성물의 제조
(Production Example 2) Production of sustained release tablet composition of the present invention
구안파신 2 중량%에 희석제로서 유당 58 중량%, 중성 수팽윤성 방출 제어용 고분자로서 하이드록시프로필메틸셀룰로스 16 중량%, 음이온성 수팽윤성 방출 제어용 고분자로서 폴리아크릴산나트륨 16 중량%, 붕해제로서 크로스카멜로스나트륨 4 중량%, 결합제로서 폴리비닐피롤리돈 3 중량% 및 윤활제로서 스테아르산마그네슘 1.0 중량%를 혼합시켜 과립화시킨 후 타정시켜 제조된 구안파신 서방성 정제 조성물을 제조한다.
By weight of guanaxanthin, 16% by weight of lactose as a diluent, 16% by weight of hydroxypropyl methylcellulose as a polymer for neutral water swellable release control, 16% by weight of sodium polyacrylate as an anionic water swellable release controlling polymer, 4% by weight of sodium, 3% by weight of polyvinylpyrrolidone as a binder, and 1.0% by weight of magnesium stearate as a lubricant were granulated and tableted to prepare a sustained release tablet composition of guanaxan.
(제조실시예 3) 본 발명의 서방성 정제 조성물의 제조
(Production Example 3) Production of sustained release tablet composition of the present invention
구안파신 2 중량%에 희석제로서 유당 62 중량%, 중성 수팽윤성 방출 제어용 고분자로서 하이드록시프로필메틸셀룰로스 14 중량%, 음이온성 수팽윤성 방출 제어용 고분자로서 폴리아크릴산나트륨 14 중량%, 붕해제로서 크로스카멜로스나트륨 4 중량%, 결합제로서 폴리비닐피롤리돈 3 중량% 및 윤활제로서 스테아르산마그네슘 1.0 중량%를 혼합시켜 과립화시킨 후 타정시켜 제조된 구안파신 서방성 정제 조성물을 제조한다.
A mixture of 2% by weight of guanaxanthin, 62% by weight of lactose as a diluent, 14% by weight of hydroxypropyl methylcellulose as a neutral water swellable release controlling polymer, 14% by weight of sodium polyacrylate as an anionic water swellable release controlling polymer, 4% by weight of sodium, 3% by weight of polyvinylpyrrolidone as a binder, and 1.0% by weight of magnesium stearate as a lubricant were granulated and tableted to prepare a sustained release tablet composition of guanaxan.
(제조비교예 1) 유당의 함량 초과 및 HPMC 불포함
(Production Comparative Example 1) Lactose content exceeded and HPMC not included
구안파신 2 중량%에 희석제로서 유당 75 중량%, 방출 제어용 고분자로서 폴리아크릴산나트륨 15 중량%, 붕해제로서 크로스카멜로스나트륨 4 중량%, 결합제로서 폴리비닐피롤리돈 3 중량% 및 윤활제로서 스테아르산마그네슘 1.0 중량%를 혼합시켜 과립화시킨 후 타정시켜 제조된 구안파신 서방성 정제 조성물을 제조한다.
A mixture of 2% by weight of guanaxanthin, 75% by weight of lactose as a diluent, 15% by weight of sodium polyacrylate as a release controlling polymer, 4% by weight of croscarmellose sodium as a disintegrant, 3% by weight of polyvinylpyrrolidone as a binder, And 1.0% by weight of magnesium are mixed to be granulated and tableted to prepare a sustained release tablet composition of Guanaxin.
(제조비교예 2) 유당의 함량 초과 및 폴리아크릴산나트륨 불포함
(Preparation Comparative Example 2) Lactose content exceeded and sodium polyacrylate was not included
구안파신 2 중량%에 희석제로서 유당 75 중량%, 방출 제어용 고분자로서 HPMC 15 중량%, 붕해제로서 크로스카멜로스나트륨 4 중량%, 결합제로서 폴리비닐피롤리돈 3 중량% 및 윤활제로서 스테아르산마그네슘 1.0 중량%를 혼합시켜 과립화시킨 후 타정시켜 제조된 구안파신 서방성 정제 조성물을 제조한다.
A mixture containing 2% by weight of guanaxanthin, 75% by weight of lactose as a diluent, 15% by weight of HPMC as a release controlling polymer, 4% by weight of croscarmellose sodium as a disintegrant, 3% by weight of polyvinylpyrrolidone as a binder, and magnesium stearate 1.0 By weight, and the mixture is granulated, followed by tableting, to prepare a sustained release sustained-release tablet composition.
(제조비교예 3) 유당의 함량 초과 및 HPMC 불포함 및 붕해제 미첨가
(Preparation Comparative Example 3) Excess of the lactose content and no HPMC and disintegration added
구안파신 2 중량%에 희석제로서 유당 79 중량%, 방출 제어용 고분자로서 폴리아크릴산나트륨 15 중량%, 결합제로서 폴리비닐피롤리돈 3 중량% 및 윤활제로서 스테아르산마그네슘 1.0 중량%를 혼합시켜 과립화시킨 후 타정시켜 제조된 구안파신 서방성 정제 조성물을 제조한다.
A mixture of 2% by weight of guanaxanthin was mixed with 79% by weight of lactose as a diluent, 15% by weight of sodium polyacrylate as a release controlling polymer, 3% by weight of polyvinylpyrrolidone as a binder and 1.0% by weight of magnesium stearate as lubricants, To prepare a sustained-release sustained-release tablet composition.
(제조비교예 4) 유당의 함량 초과, 폴리아크릴산나트륨 불포함 및 결합제 미첨가
(Preparation Comparative Example 4) Excess of the content of lactose, no sodium polyacrylate, and no binder
구안파신 2 중량%에 희석제로서 유당 78 중량%, 방출 제어용 고분자로서 HPMC 15 중량%, 붕해제로서 크로스카멜로스나트륨 4 중량% 및 윤활제로서 스테아르산마그네슘 1.0 중량%를 혼합시켜 과립화시킨 후 타정시켜 제조된 구안파신 서방성 정제 조성물을 제조한다.
To 2% by weight of guanaxanthin was mixed 78% by weight of lactose as a diluent, 15% by weight of HPMC as a release controlling polymer, 4% by weight of croscarmellose sodium as disintegrant and 1.0% by weight of magnesium stearate as a lubricant, To prepare a sustained release sustained release tablet composition.
(제조비교예 5) 유당 함량 초과, 폴리아크릴산나트륨 불포함 및 윤활제 미첨가
(Preparation Comparative Example 5) Excess lactose content, no sodium polyacrylate, and no added lubricant
구안파신 2 중량%에 희석제로서 유당 76 중량%, 방출 제어용 고분자로서 HPMC 15 중량%, 붕해제로서 크로스카멜로스나트륨 4 중량% 및 결합제로서 폴리비닐피롤리돈 3 중량%를 혼합시켜 과립화시킨 후 타정시켜 제조된 구안파신 서방성 정제 조성물을 제조한다.
A mixture of 2% by weight of guanaxanthin was mixed with 76% by weight of lactose as a diluent, 15% by weight of HPMC as a release controlling polymer, 4% by weight of croscarmellose sodium as a disintegrant and 3% by weight of polyvinylpyrrolidone as a binder, To prepare a sustained-release sustained-release tablet composition.
(실시예 1) 용출 시험
(Example 1) Dissolution test
제조실시예 1, 제조비교예 1, 3, 4 및 5에서 제조한 정제를 대한약전 제8 개정판 패들 방법으로 다음과 같은 조건 하에서 용출 시험을 실시하고 유효 활성성분인 구안파신의 용출율을 시간 경과에 따라 측정하였다.
Preparation Example 1 Preparation The tablets prepared in Comparative Examples 1, 3, 4 and 5 were subjected to a dissolution test under the following conditions by the paddle method of the Pharmacopoeia No. 8 plate, and the dissolution rate of guanofen, which is an active ingredient, Respectively.
용출시험액 : 대한약전 붕해시험법 제 2액(pH 6.8), 900ml, 37±0.5℃Dissolution Test Solution: The second solution (pH 6.8) of the Korean Pharmacopoeia Disintegration Test Method, 900 ml, 37 ± 0.5 ° C
용출방법 : 대한약전 용출시험 제 2법(패들법), 분당 50 회전
Elution method: Korean Pharmacopoeia dissolution test Method 2 (paddle method), 50 rotations per minute
상기 용출시험에서 시간마다 획득한 검액으로부터 활성성분의 용출율을 분석하였다. 시료채취는 시료채취 시간마다 용출액을 취해 0.45㎛ 필터로 여과하여 검액으로 하고 용출액을 취한 후에는 새로운 용출액을 동량 보정해주었다. 용출율 분석은 HPLC를 사용하여 분석하였으며 시간의 경과에 따른 용출율 시험 결과를 도 1에 나타내었다.
In the dissolution test, the dissolution rate of the active ingredient was analyzed from the obtained solution at each time point. Sampling was carried out by sampling the eluate at each sampling time, filtering it with a 0.45 μm filter to prepare a sample solution, taking out the eluate, and then calibrating the new eluate by the same amount. The dissolution rate was analyzed using HPLC and the dissolution rate test results over time are shown in FIG.
도 1에 나타난 바와 같이 본 발명 제조실시예 1에서 제조된 구안파신 서방성 정제 조성물의 경우 10시간 이후에는 90% 이상의 안정적인 용출을 나타내었으나 제조비교에 1에서 제조된 정제 조성물의 경우 제조실시예 1에서 제조된 구안파신 서방성 정제 조성물보다 측정 시간별로 5~10% 정도 감소한 용출율을 나타내었으며 제조비교예 3, 제조비교예 4, 제조비교예 5에서 제조된 정제 조성물의 경우 제조비교예 1에서 제조된 정제 조성물보다도 시간별로 5~20% 정도 감소한 용출율을 나타내었다.
As shown in FIG. 1, in the case of the slow-release sustained-release tablet composition prepared in Example 1 of the present invention, stable elution was observed at 90% or more after 10 hours, but in the case of the tablet composition prepared in Comparative Example 1, The purified composition prepared in Comparative Preparation Example 3, Comparative Preparation Example 4, and Preparation Comparative Example 5 exhibited a dissolution rate lower by 5 to 10% than that of the sustained- And the dissolution rate was decreased by 5 ~ 20% over time as compared with the purified tablet composition.
이와 같은 용출 곡선을 통해 본 발명의 제조실시예 1에서 제조된 구안파신 서방성 정제 조성물이 신속한 시간 내에 충분히 용출되며 지속적인 용출 패턴을 나타내는 것이 확인되었다.
Through the elution curve, it was confirmed that the sustained elution pattern was sufficiently eluted within a short period of time, and the sustained elution pattern of the Guillaz-parsonic sustained-release tablet composition prepared in Production Example 1 of the present invention was confirmed.
(실시예 2) 안정성시험
(Example 2) Stability test
제조실시예 1 및 제조비교예 1, 2, 3 및 4에서 제조한 정제를 PTP포장 후 가속조건인 40℃, 상대습도 75%에서 6개월 간 보관하여 고속액체크로마토그래피에 의해 구안파신의 함량을 측정하고 그 결과를 표 1에 나타내었다.
Preparation Example 1 and Production The tablets prepared in Comparative Examples 1, 2, 3 and 4 were stored for 6 months at 40 ° C. and 75% relative humidity after acceleration of the packing of PTP, and the content of goaxin was measured by high performance liquid chromatography And the results are shown in Table 1.
상기 표 1에 나타난 바와 같이 본 발명 제조실시예 1에서 제조된 구안파신 서방성 정제 조성물은 가속조건 하에서 6개월 동안 경시 변화를 관찰한 결과 매우 안정적인 정제 제형임을 확인할 수 있었다.
As shown in Table 1, the sustained-release composition of the sustained-release sustained-release preparations of Example 1 of the present invention was found to be a stable tablet formulation after 6 months under accelerated conditions.
그러나 제조비교예 1에서 제조된 구안파신 서방성 정제 조성물은 6개월 후 함량이 92.4%로서 기준에는 적합한 것이었으나 경시 변화에 따른 함량 감소가 상당히 이루어진 것을 알 수 있었다. 또한 제조비교에 2, 3, 4에서 제조된 구안파신 서방성 정제 조성물의 경우 6개월 후 함량이 기준인 90%에 미치지 못하는 것으로 경시 변화에 따른 함량 감소로 인해 적합하지 않은 정제 제형임을 확인하였다.However, the composition of sustained release tablets prepared in Comparative Preparation Example 1 was 92.4% after 6 months, which was appropriate for the standard, but it was found that the content decreased considerably with time. In addition, the sustained release tablets prepared in Comparative Examples 2, 3 and 4 showed less than 90% of the standard tablet content after 6 months, indicating that the tablets were not suitable due to the decrease in the content with time.
Claims (4)
By weight of guanaxanthin, 13 to 17% by weight of lactose as a diluent, 13 to 17% by weight of hydroxypropylmethyl cellulose as a neutral water-swellable release-controlling polymer, 13 to 17% by weight of sodium polyacrylate as an anionic water- As a disintegrant, 3 to 5% by weight of croscarmellose sodium, 2 to 4% by weight of polyvinylpyrrolidone as a binder, and 0.8 to 1.2% by weight of magnesium stearate as a lubricant, granulating the mixture, Wherein the content of guanaxin as an active ingredient is 0.5 to 4 mg in the composition for oral cavity tablets,
ⅱ) 건조된 과립화 혼합물을 정제로 압착 타정시키는 단계;
로 이루어진 구안파신 서방성 정제 조성물의 제조 방법
I) 55 to 65% by weight of lactose as a diluent, 13 to 17% by weight of hydroxypropyl methylcellulose as a neutral water swellable release controlling polymer, 13 to 17% by weight of sodium polyacrylate as an anionic water swellable release controlling polymer 3 to 5% by weight of sodium croscarmellose as a disintegrant, 2 to 4% by weight of polyvinylpyrrolidone as a binder and 0.8 to 1.2% by weight of magnesium stearate as a lubricant, Pulverizing and granulating; And
Ii) crushing the dried granulation mixture with a tablet;
≪ / RTI >
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020120146171A KR101462065B1 (en) | 2012-12-14 | 2012-12-14 | Oral pharmaceutical composition for sustained release containing guanfacine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020120146171A KR101462065B1 (en) | 2012-12-14 | 2012-12-14 | Oral pharmaceutical composition for sustained release containing guanfacine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20130008496A KR20130008496A (en) | 2013-01-22 |
| KR101462065B1 true KR101462065B1 (en) | 2014-11-14 |
Family
ID=47838565
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020120146171A KR101462065B1 (en) | 2012-12-14 | 2012-12-14 | Oral pharmaceutical composition for sustained release containing guanfacine |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101462065B1 (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20090109113A (en) * | 2007-01-25 | 2009-10-19 | 파나세아 바이오테크 리미티드 | Modified Release Pharmaceutical Composition and a Process of making the same |
-
2012
- 2012-12-14 KR KR1020120146171A patent/KR101462065B1/en active IP Right Grant
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20090109113A (en) * | 2007-01-25 | 2009-10-19 | 파나세아 바이오테크 리미티드 | Modified Release Pharmaceutical Composition and a Process of making the same |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20130008496A (en) | 2013-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2974720B1 (en) | Mosapride sustained-release preparation for providing pharmacological clinical effects with once-a-day administration | |
| JP4340840B2 (en) | Sustained release pharmaceutical dosage form with minimized pH dependent dissolution profile | |
| US20060088594A1 (en) | Highly compressible controlled delivery compositions of metformin | |
| CN106943355B (en) | Pharmaceutical composition | |
| KR100780553B1 (en) | Pharmaceutical compositions and formulations of Metformin extended release tablets and its preparing method | |
| WO2006082523A2 (en) | Pharmaceutical sustained release composition of metformin | |
| JP2005508331A (en) | Dosage preparation for the treatment of diabetes | |
| WO2014104671A1 (en) | Pharmaceutical composition with improved stability, containing temozolomide, and preparation method therefor | |
| CN111840239B (en) | Pregabalin sustained release preparation | |
| CN109875972B (en) | Olmesartan medoxomil and amlodipine pharmaceutical composition | |
| AU2019232937B2 (en) | Ceritinib formulation | |
| KR101485421B1 (en) | Controlled-release Oral Drug Preparations and it's Manufacturing Process Containing Itopride Hydrochloride | |
| WO2006123213A1 (en) | Modified release formulations of gliclazide | |
| WO2015044375A1 (en) | Pharmaceutical preparation comprising dabigatran etexilate bismesylate | |
| KR101462065B1 (en) | Oral pharmaceutical composition for sustained release containing guanfacine | |
| EP2190419A1 (en) | Multi particulate matrix system containing galantamine | |
| KR101446066B1 (en) | Oral capsule composition for sustained release containing guanfacine | |
| CN100490808C (en) | Gliquilone slow-releasing preparation | |
| EP3511001B1 (en) | Pirfenidone-containing tablet and capsule formulation | |
| KR101175816B1 (en) | Sustained release tablet for oral use | |
| EP2044933A1 (en) | Multi particulate matrix system containing galantamine | |
| KR20100037737A (en) | Trimebutine slow -releasing tablet having improved releasing rate and convenience for internal use | |
| KR101798184B1 (en) | Composition for Controlled Release of Drug | |
| KR100804829B1 (en) | Pharmaceutical compositions for oral administration containing nateglinide | |
| WO2020249500A1 (en) | Stable tablet formulation of nifurtimox and process for producing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20170907 Year of fee payment: 4 |
|
| FPAY | Annual fee payment |
Payment date: 20180919 Year of fee payment: 5 |
|
| FPAY | Annual fee payment |
Payment date: 20191028 Year of fee payment: 6 |